Cell and gene therapy companies develop advanced treatments that modify, replace or engineer cells and genetic material to treat disease. The field is one of the fastest-growing areas of biotechnology and precision medicine.
This category includes companies working on:
Browse 163 UK cell and gene therapy companies below.
Automated single-cell isolation and cloning instruments for cell biology
Iota Sciences is a developer of automated single-cell handling instruments and cell-line engineering services. The company's platform automates single-cell isolation and cloning in nanolitre volumes, supporting monoclonal cell line development with integrated viability monitoring and documentation. GRID Technology…
High-throughput iPSC reprogramming and stem cell drug discovery services
Oxford StemTech is a contract research company providing induced pluripotent stem cell (iPSC) reprogramming and drug discovery services using its proprietary platform. The technology enables large-scale, cost-effective generation of patient-derived iPSC lines from blood or skin samples, supporting disease modelling,…
AI-driven T-cell receptor discovery platform for solid tumour immunotherapies
Exogene is an Oxford biotech developing TCR-based immunotherapies for solid tumours. Its platform integrates generative AI, biophysical simulation, and high-throughput TCR-antigen screening to identify rare, high-affinity cancer-specific T-cell receptors from patient tumour samples. The company develops TCR-T cell…
AAV gene therapies for rare neurological diseases of childhood
BlackfinBio is a biotechnology company developing AAV-based gene therapies for rare neurodegenerative diseases of the central nervous system, with an initial focus on children. Its lead programme is a one-time gene therapy administered directly to the brain, designed to treat a group of ultra-rare dopamine deficiency…
Lentiviral gene therapy developer for tumours and rare diseases
Santo Therapeutics develops in vivo lentiviral gene therapies for cancer and rare genetic disorders. Its proprietary vector platform supports programmes including ST002, an NF2 gene-replacement therapy for NF2-related schwannomatosis. The company announced the start of an investigator-initiated clinical trial of ST002…
Gene therapy platform targeting paediatric solid tumours
Kindling Bio is a biotechnology company developing a gene therapy platform designed specifically for childhood cancers. The platform engineers a biological signal that renders paediatric solid tumours visible to the immune system, enabling immune-mediated destruction across multiple tumour types from a single…
Manufacturing management software for cell and gene therapy production
Autolomous is a software company developing cloud-native manufacturing management systems for cell and gene therapy production. Its platform digitises and integrates the full GMP manufacturing workflow, covering data capture, batch verification, quality release, process analytical technology, and operational logistics…
AAV gene therapy targeting the seizure focus in refractory epilepsy
Focalis Bio is a biotechnology company developing gene therapies for focal refractory epilepsy, a condition in which seizures arise from a specific brain region and do not respond to antiseizure medicines. Its lead programme, EPY201, is an AAV9-based gene therapy delivered locally via catheter directly to the…
Human iPSC-derived disease models and drug discovery services
Axol Bioscience is a biotechnology company supplying human induced pluripotent stem cell-derived cells and research services for disease modelling and drug discovery. Its portfolio includes neurons, cardiomyocytes, retinal organoids, retinal pigment epithelium and skin cell models, alongside culture media and custom…
In vivo lentiviral CAR/TCR cell therapy platform for ovarian cancer
Akimbo Bio is an early-stage biotechnology company developing next-generation in vivo lentiviral vector technology for cell therapy. Its lead platform carries a dual CAR/TCR payload designed for direct in vivo delivery, with an initial focus on ovarian cancer. The technology uses intelligent receptor crosstalk, in…
Targeted nanoparticles for in vivo CAR-T and gene delivery
Deliver Biosciences is a biotechnology company developing targeted nanoparticle vectors for in vivo cell and gene therapies. Its delivery platform transports genetic payloads, including DNA and mRNA, into selected cell types using programmable targeting components. Its lead programme aims to engineer T cells inside…
Combinatorial stem cell screening platform for therapy development
Plasticell is a biotechnology company developing cell and gene therapies and enabling drug discovery through its proprietary platform. The technology uses bead-based combinatorial screening to test thousands of cell culture variable combinations in parallel, identifying optimised protocols for stem cell expansion,…
AAV gene therapies for rare and neurological diseases
Spur Therapeutics is a clinical-stage biotechnology company developing adeno-associated virus-based gene therapies for serious chronic diseases. Its lead programme is a Phase I/II gene therapy for Gaucher disease type 1, a rare lysosomal storage disorder. Further pipeline candidates target GBA1 Parkinson's disease and…
Specialist oncology clinical trial management for biotech and pharma
Karma Oncology is a specialist contract research organisation providing full-service and functional clinical trial management to biotechnology and pharmaceutical companies in oncology. Operating as a lean virtual CRO, the company offers clinical development planning, protocol design, site selection and activation,…
Bispecific TCR therapies targeting HLA-Class II cancer antigens
Yellowstone Biosciences is a pre-clinical biotechnology company developing bispecific T-cell receptor therapies for oncology. The company targets a novel class of HLA Class II antigens expressed across multiple cancers, with an initial programme focused on acute myeloid leukaemia. Its approach is designed to…
Hypothermic gel preservation technology for shipping cells
Atelerix is a biotechnology company supplying hydrogel-based cell and tissue preservation products that eliminate the need for cryogenic cold chain logistics. Its patented alginate encapsulation technology maintains cell viability at ambient temperatures for up to fourteen days, enabling the shipment of cells,…
Automated robotic systems for cell therapy and stem cell manufacture
Sakarta is an instruments and equipment company developing automated robotic solutions for cell therapy and stem cell manufacturing. Working with partners in the UK and Japan, it is commercialising a closed automated cell culture instrument incorporating real-time process analytical technology. The platform automates…
Ex vivo haematopoietic stem cell gene therapies for rare genetic diseases
Orchard Therapeutics is a gene therapy company developing ex vivo haematopoietic stem cell therapies for rare genetic diseases, primarily severe neurometabolic and immunological disorders in children. Its platform modifies a patient's own stem cells with a functional copy of the defective gene before reinfusion. Lead…
AAV gene therapies for neurodegenerative diseases including FTD and ALS
AviadoBio is a clinical-stage gene therapy company developing AAV-based treatments for neurodegenerative diseases. Its lead programme, AVB-101, is in a Phase 1/2 trial for frontotemporal dementia caused by GRN gene mutations, delivering a functional copy of the GRN gene via intrathalamic infusion to restore…
Nanoparticle platform for targeted genetic medicine delivery
ViaNautis is a nanomedicine company developing a polymer nanoparticle platform for the targeted intracellular delivery of genetic therapeutic payloads across difficult-to-penetrate biological barriers. The platform is designed to encapsulate a broad range of genetic cargoes and guide them to specific tissues and cell…